Top of page
Skip to main content
Main content

Gavegnano Lab Accomplishments

FDA Approved Drug

Baricitinib for the use of COVID-19, first line treatment status worldwide; greatest reduction in mortality above any standard of care.

Multiple ongoing human trials

  • Phase 2a study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system.
  • Elucidating the role of the gut reservoir and inflammation in driving cardiovascular disease among persons living with HIV (non-interventional)
  • Phase 2a study to evaluate baricitinib to reverse treatment resistant depression in people living with HIV.
  • Phase 3 study REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (With Baricitinib) for Long COVID Related Cognitive Impairment and ADRD (Alzheimer's Disease and Related Dementias)